Parish Sedghizadeh

Last updated
ISBN 978-1-60795-192-6.
  • Sedghizadeh PP, Jones AC. Chapter 12: Osteonecrosis of the jaw. In: The Duration and Safety of Osteoporosis Treatment: Anabolic and Antiresorptive Therapy. Silverman and Abrahamsen, eds. Springer, 2015; ISBN   978-3-319-23639-1.
  • Related Research Articles

    Phossy jaw, formally known as phosphorus necrosis of the jaw, was an occupational disease affecting those who worked with white phosphorus without proper safeguards. It was most commonly seen in workers in the matchstick industry in the 19th and early 20th centuries. It was caused by white phosphorus vapor, which destroys the bones of the jaw. Modern occupational hygiene practices have since eliminated the working conditions that caused this disease.

    <span class="mw-page-title-main">Alendronic acid</span> Chemical compound

    Alendronic acid, sold under the brand name Fosamax among others, is a bisphosphonate medication used to treat osteoporosis and Paget's disease of bone. It is taken by mouth. Use is often recommended together with vitamin D, calcium supplementation, and lifestyle changes.

    <span class="mw-page-title-main">Dental implant</span> Surgical component that interfaces with the bone of the jaw

    A dental implant is a prosthesis that interfaces with the bone of the jaw or skull to support a dental prosthesis such as a crown, bridge, denture, or facial prosthesis or to act as an orthodontic anchor. The basis for modern dental implants is a biological process called osseointegration, in which materials such as titanium or zirconia form an intimate bond to the bone. The implant fixture is first placed so that it is likely to osseointegrate, then a dental prosthetic is added. A variable amount of healing time is required for osseointegration before either the dental prosthetic is attached to the implant or an abutment is placed which will hold a dental prosthetic/crown.

    <span class="mw-page-title-main">Avascular necrosis</span> Death of bone tissue due to interruption of the blood supply

    Avascular necrosis (AVN), also called osteonecrosis or bone infarction, is death of bone tissue due to interruption of the blood supply. Early on, there may be no symptoms. Gradually joint pain may develop which may limit the ability to move. Complications may include collapse of the bone or nearby joint surface.

    Dental plaque is a biofilm of microorganisms that grows on surfaces within the mouth. It is a sticky colorless deposit at first, but when it forms tartar, it is often brown or pale yellow. It is commonly found between the teeth, on the front of teeth, behind teeth, on chewing surfaces, along the gumline (supragingival), or below the gumline cervical margins (subgingival). Dental plaque is also known as microbial plaque, oral biofilm, dental biofilm, dental plaque biofilm or bacterial plaque biofilm. Bacterial plaque is one of the major causes for dental decay and gum disease.

    <span class="mw-page-title-main">Pamidronic acid</span> Chemical compound

    Pamidronic acid or pamidronate disodium or APD, is a nitrogen-containing bisphosphonate used to prevent osteoporosis.

    SAPHO syndrome includes a variety of inflammatory bone disorders that may be associated with skin changes. These diseases share some clinical, radiologic, and pathologic characteristics.

    <span class="mw-page-title-main">Dental extraction</span> Operation to remove a tooth

    A dental extraction is the removal of teeth from the dental alveolus (socket) in the alveolar bone. Extractions are performed for a wide variety of reasons, but most commonly to remove teeth which have become unrestorable through tooth decay, periodontal disease, or dental trauma, especially when they are associated with toothache. Sometimes impacted wisdom teeth cause recurrent infections of the gum (pericoronitis), and may be removed when other conservative treatments have failed. In orthodontics, if the teeth are crowded, healthy teeth may be extracted to create space so the rest of the teeth can be straightened.

    <span class="mw-page-title-main">Dentinogenesis imperfecta</span> Medical condition

    Dentinogenesis imperfecta (DI) is a genetic disorder of tooth development. It is inherited in an autosomal dominant pattern, as a result of mutations on chromosome 4q21, in the dentine sialophosphoprotein gene (DSPP). It is one of the most frequently occurring autosomal dominant features in humans. Dentinogenesis imperfecta affects an estimated 1 in 6,000-8,000 people.

    An oral medicine or stomatology doctor/dentist has received additional specialized training and experience in the diagnosis and management of oral mucosal abnormalities including oral cancer, salivary gland disorders, temporomandibular disorders and facial pain, taste and smell disorders; and recognition of the oral manifestations of systemic and infectious diseases. It lies at the interface between medicine and dentistry. An oral medicine doctor is trained to diagnose and manage patients with disorders of the orofacial region, essentially as a "physician of the mouth".

    <span class="mw-page-title-main">Ibandronic acid</span> Chemical compound

    Ibandronic acid is a bisphosphonate medication used in the prevention and treatment of osteoporosis and metastasis-associated skeletal fractures in people with cancer. It may also be used to treat hypercalcemia. It is typically formulated as its sodium salt ibandronate sodium.

    <span class="mw-page-title-main">Osteonecrosis of the jaw</span> Medical condition

    Osteonecrosis of the jaw (ONJ) is a severe bone disease (osteonecrosis) that affects the jaws. Various forms of ONJ have been described since 1861, and a number of causes have been suggested in the literature.

    <span class="mw-page-title-main">Denosumab</span> Human monoclonal antibody

    Denosumab is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

    Targanta Therapeutics Corporation was a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company also had operations in Indianapolis, Montreal and Toronto. Targanta completed its initial public offering on October 9, 2007 and traded on the Nasdaq market under the symbol: TARG. Targanta was acquired by The Medicines Company in 2009.

    <span class="mw-page-title-main">Medication-related osteonecrosis of the jaw</span> Medical condition

    Medication-related osteonecrosis of the jaw is progressive death of the jawbone in a person exposed to a medication known to increase the risk of disease, in the absence of a previous radiation treatment. It may lead to surgical complication in the form of impaired wound healing following oral and maxillofacial surgery, periodontal surgery, or endodontic therapy.

    Neuralgia-inducing cavitational osteonecrosis (NICO) is a diagnosis whereby a putative jawbone cavitation causes chronic facial neuralgia; this is different from osteonecrosis of the jaw. In NICO the pain is said to result from the degenerating nerve ("neuralagia"). The condition is probably rare, if it does exist.

    <span class="mw-page-title-main">C-terminal telopeptide</span> Chemical compound

    The C-terminal telopeptide (CTX), also known as carboxy-terminal collagen crosslinks, is the C-terminal telopeptide of fibrillar collagens such as collagen type I and type II. It is used as a biomarker in the serum to measure the rate of bone turnover. It can be useful in assisting clinicians to determine a patient's nonsurgical treatment response as well as evaluate a patient's risk of developing complications during healing following surgical intervention. The test used to detect the CTX marker is called the Serum CrossLaps, and it is more specific to bone resorption than any other test currently available.

    Osteomyelitis of the jaws is osteomyelitis which occurs in the bones of the jaws. Historically, osteomyelitis of the jaws was a common complication of odontogenic infection. Before the antibiotic era, it was frequently a fatal condition.

    <span class="mw-page-title-main">Tooth mobility</span> Medical condition

    Tooth mobility is the horizontal or vertical displacement of a tooth beyond its normal physiological boundaries around the gingival area, i.e. the medical term for a loose tooth.

    Oral manifestations of systematic disease are signs and symptoms of disease occurring elsewhere in the body detected in the oral cavity and oral secretions. High blood sugar can be detected by sampling saliva. Saliva sampling may be a non-invasive way to detect changes in the gut microbiome and changes in systemic disease. Another example is tertiary syphilis, where changes to teeth can occur. Syphilis infection can be associated with longitudinal furrows of the tongue.

    References

    1. 1 2 3 4 5 "Parish Sedghizadeh".
    2. 1 2 "Parish Sedghizadeh - Google Scholar".
    3. "Parish Sedghizadeh".
    4. "Dr. Parish Sedghizadeh".
    5. "Sedghizadeh receives $1.5 million for bone infection treatment".
    6. "BioVinc Receives an STTR Phase II Grant from NIH".
    7. "Microbial Biofilms in Osteomyelitis of the Jaw and Osteonecrosis of the Jaw Secondary to Bisphosphonate Therapy".
    8. "The in vivo Th17 and Treg immune responses to Aggregatibacter actinomycetemcomitans".
    9. Sedghizadeh, Parish P.; Chen, Meng-Tse; Schaudinn, Christoph; Gorur, Amita; Jiang, Chunqi (2012). "Inactivation Kinetics Study of an Atmospheric-Pressure Cold-Plasma Jet Against Pathogenic Microorganisms". IEEE Transactions on Plasma Science. 40 (11): 2879. Bibcode:2012ITPS...40.2879S. doi:10.1109/TPS.2012.2213306. S2CID   41477910.
    10. Junka, A.; Wojtowicz, W.; Ząbek, A.; Krasowski, G.; Smutnicka, D.; Bakalorz, B.; Boruta, A.; Dziadas, M.; Młynarz, P.; Sedghizadeh, P. P.; Bartoszewicz, M. (2017). "Metabolic profiles of exudates from chronic leg ulcerations". Journal of Pharmaceutical and Biomedical Analysis. 137: 13–22. doi:10.1016/j.jpba.2017.01.018. PMID   28088662. S2CID   31007513.
    11. Karasneh, J. A.; Al-Eryani, K.; Clark, G. T.; Sedghizadeh, P. P. (2016). "Modified protocol including topical minocycline in orabase to manage medication-related osteonecrosis of the jaw cases". Journal of Oral Pathology & Medicine. 45 (9): 718–720. doi:10.1111/jop.12419. PMID   26750149.
    12. Sedghizadeh, P. P.; Jones, A. C.; Lavallee, C.; Jelliffe, R. W.; Le, A. D.; Lee, P.; Kiss, A.; Neely, M. (2012). "Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw". Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 115 (2): 224–232. doi:10.1016/j.oooo.2012.08.455. PMC   3545087 . PMID   23246224.
    13. Enciso, R.; Keaton, J.; Saleh, N.; Ahmadieh, A.; Clark, G. T.; Sedghizadeh, P. P. (2016). "Assessing the utility of sCTX as a predictor for the development of BRONJ: A systematic review and meta-analysis". Journal of the American Dental Association. 147 (7): 551–560.e11. doi:10.1016/j.adaj.2016.02.011. PMID   27040417.
    14. Schaudinn, C.; Gorur, A.; Webster, P.; Jones, A. C.; Neely, M.; Jelliffe, R. W.; Le, A. D.; Sedghizadeh, P. P. (2012). "Quantification by energy dispersive x-ray spectroscopy of alendronate in the diseased jaw bone of patients with bisphosphonate-related jaw osteonecrosis". Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 114 (4): 480–6. doi:10.1016/j.oooo.2012.06.006. PMID   22986243.
    15. "International Research Promotion Council names USC dentist 'Eminent Scientist of the Year'". 22 March 2007.
    16. "The 2009 Charles E. English Annual Award in Clinical Science and Techniques". Implant Dentistry. 19 (3): 176. 2010. doi: 10.1097/ID.0b013e3181e35f08 .
    17. "CDA Wrap-Up: Ostrow receives several awards and honors".
    Parish Sedghizadeh
    Academic background
    EducationB.S., Biology
    D.D.S., Dentistry
    M.S.,Oral Biology
    Alma mater University of California, Los Angeles
    University of Southern California
    Ohio State University